Home
overview
A very interesting and forward looking program
Dr Denis Miller, Senior Medical Director, Therapeutic Area Clinical Practice Leader, Haematology/Oncology, PAREXEL

The field of oncology is indeed on the brink of impressive advancements utilizing imaging technologies."
Dr Kenna Anderes, Associate Research Fellow, Cancer Biology, Pfizer Global R&D

As medical imaging in oncology matures it is imperative to realise the benefits of technology at the earliest stage possible in order to diagnose cancer earlier and treat patients faster. Whether this involves using nanotechnology, non invasive visible light or a pharmaceutical scope of locked nucleic acid, pharmaceutical companies need to be utilizing these in order to gain a foothold in the oncology arena.

Our distinguished speaker line-up includes:

  • Dr Paul Maguire, Associate Director, Global Clinical Technology, Global Research and Development, Pfizer*
  • Dr Philip Murphy, Associate Director, Pfizer
  • Dr Haren Rupani, Global Head, Oncology Imaging, Novartis Pharmaceuticals
  • Dr Werner Scheuer, Group Leader, Preclinical Optical Imaging, Pharmacology TR-PD, Pharmaceutical Research, Roche Diagnostics
  • Dr Peter Lassota, Divisional Vice President, Oncology, Caliper Life Sciences
  • Bo Hansen, Associate Director, Molecular Biology, Santaris Pharma
  • Dr C Carl Jaffe, Branch Chief, Diagnostic Imaging Branch, Cancer Imaging Program, Cancer Treatment and Diagnosis Division, National Cancer Institute, USA
  • Dr Jean-Luc Vanderheyden, Global Molecular Imaging Leader, Technology and Medical Office, GE Healthcare
  • Dr Heinz-Otto Peitgen, President, MeVis-Center for Diagnostics Systems and Visualization
  • Professor Tobias Schaeffter, Philip Harris Chair in Imaging Sciences, Division of Imaging Sciences, King's College London
  • Dr Jimmy Bell, Group Head, In Vivo Imaging Section, Molecular Imaging, MRC Clinical Sciences Centre, Imperial College, London

Chaired by:
  • Dr Patricia Cole, Senior Director and Head, Imaging Programmes, Eisai
  • Dr Karol Sikora, Scientific Director, Oncology, Medical Solutions and Professor, Cancer Medicine, Imperial College, London

*Presentation will be via tele-conference

This exciting conference will:

  • PROVIDE cutting edge insights and practical information on the latest developments affecting this rapidly evolving field
  • OFFER an understanding of the importance of R&D into novel therapies such as molecular agents and nanotechnology
  • DISCUSS the application of current and innovative imaging technologies and developments in oncology
  • EXAMINE the importance of translational studies and how to bridge the preclinical to clinical divide
  • EMPHASISE how to develop and incorporate imaging solutions that lead to earlier diagnosis

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Karol Sikora

Dr Karol Sikora, Scientific Director, Oncology, Medical Solutions and Professor, Cancer Medicine, Imperial College, London

9:10 PET METHODOLOGY AND ITS APPLICATION TO DRUG DEVELOPMENT IN ONCOLOGY

Dr Julian  Matthews

Dr Julian Matthews , Head, Data Analysis, Wolfson Molecular Imaging Centre, The University of Manchester

  • Overview of PET technology
  • Pharmacokinetic measurement
  • In Vivo competition assays
  • Pharmacodynamic response
  • Other applications
  • 9:50 IMPACT OF MOLECULAR IMAGING

    Dr Jean-Luc Vanderheyden

    Dr Jean-Luc Vanderheyden, Global Molecular Imaging Leader, Technology and Medical Office, GE Healthcare

  • Applications within both pre-clinical and clinical research
  • Assessing pathways of fundamental processes in oncology
  • Beyond enrichment of patient populations
  • Treatment response for business or regulatory decision-making
  • Differential diagnosis and therapeutic decision-making
  • 10:30 Morning Coffee

    10:50 NON INVASIVE VISIBLE LIGHT IMAGING IN DRUG DISCOVERY AND DEVELOPMENT

    Dr Peter Lassota

    Dr Peter Lassota, Divisional Vice President, Oncology , Caliper Life Sciences

  • Light emitting transgenic mice in drug discovery
  • Designing screening assays with animal studies in mind: bridging the in vitro/in vivo gap
  • Choosing the right imaging modality: two can be better than one
  • Clinic: the final frontier. Will light be with us there?
  • 11:30 INTEGRATING PHARMACOLOGY IMAGING AND ANIMAL MODELS IN CANCER DRUG EVALUATIONS

    Xavier Tizon

    Xavier Tizon, MRI Lab Manager, Oncodesign

  • What’s new about experimental cancer models: does there exist a universal model?
  • From rat models to patients: proof of cancer
  • Doing translational research with MRI and PET
  • Early determination of efficacy biomarkers: antiangiogenic agent and MRI
  • Development of an optimised schedule of administration for a combination study based on biomarker imaging
  • 12:10 INTERACTIVE PANEL DISCUSSION

    Dr Karol Sikora

    Dr Karol Sikora, Scientific Director, Oncology, Medical Solutions and Professor, Cancer Medicine, Imperial College, London

    Dr Haren Rupani

    Dr Haren Rupani, Global Head, Oncology Imaging, Novartis

    Dr Donald Rosen

    Dr Donald Rosen, Founder and Chief Strategic Officer, RadPharm

    Dr Patricia Cole

    Dr Patricia Cole, Senior Director and Head, Imaging Programmes, Eisai

    12:50 Networking Lunch

    14:20 MEDICAL IMAGING PLATFORMS FOR CLINICAL TRIALS

    David La Point

    David La Point, Vice President, Business Development, Beacon Bioscience

  • Understand the nature of digital imaging data
  • Understand what FDA is looking for in charters and image based submissions
  • React to adaptive designs within a platform
  • Develop internal expertise and tools for maximizing the image data
  • Development of an image-based knowledge tool
  • 15:00 LESSONS LEARNED IN ONCOLOGY CLINICAL TRIALS

    Dr Donald Rosen

    Dr Donald Rosen, Founder and Chief Strategic Officer, RadPharm

  • Rational for the use of blinded independent central review for oncology clinical trials
  • Our experience having performed the image review in over 200 global oncology clinical trials
  • The justification presented in the literature
  • The regulatory opinion
  • Independent eligibility review of images in oncology clinical trials
  • 15:40 Afternoon Tea

    16:00 STANDARDIZATION IN ONCOLOGY FUNCTIONAL BIOMARKERS

    Dr Paul Maguire

    Dr Paul Maguire, Associate Director, Global Technology Group, Oncology Thepapeutic Area, Pfizer*

  • Applications of functional imaging markers in oncology
  • Standardization hurdles to biomarker application
  • Industrial requirements
  • Protocol standardization needs
  • Current developments
  • 16:40 IMAGING IN CLINICAL TRIALS

    Dr C Carl Jaffe

    Dr C Carl Jaffe, Branch Chief, Diagnostic Imaging Branch, Cancer Imaging Program, Cancer Treatment and Diagnosis Division, National Cancer Institute, USA

  • Ongoing efforts to standardise image acquisition
  • Coping with technology advancement and equipment variation by different manufacturers
  • Uniform analysis measures for: anatomic, dynamic and molecular imaging techniques
  • Accrual effects of protocols variation amongst different institutions
  • Image 'charters', quality monitoring and image auditing
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Patricia Cole

    Dr Patricia Cole, Senior Director and Head, Imaging Programmes, Eisai

    9:10 PRACTICAL CONSIDERATIONS FOR IMAGING IN CLINICAL TRIALS

    Dr Haren Rupani

    Dr Haren Rupani, Global Head, Oncology Imaging, Novartis

  • Imaging modalities used in clinical trials and current state of art
  • The do's and don’ts of conducting a multinational, multicenter trial
  • The importance of public-private partnerships
  • 9:50 EMERGING TREATMENTS IN ONCOLOGY

    Dr Philip Murphy

    Dr Philip Murphy, Associate Director, Pfizer

  • Examining who the simplicity of RECIST technique contrasts with the increasing sophistication of imaging instrumentation
  • Improvements to methodoligic robustness in light of functionally-based imaging
  • Characterizing tumor response to therapy as a complement to image acquisition
  • Incorporating design
  • 10:30 Morning Coffee

    11:00 COMPUTATIONAL CLINICAL IMAGING

    Dr Volker Dicken

    Dr Volker Dicken, Lead Scientist, Oncological Imaging, MeVis Research, Center for Medical Image Computing

  • Examples of medical image computing
  • CT morphology: underestimated in oncological imaging?
  • Understanding the importance of partial volume effects and measurement errors
  • Chances of software assisted lesion segmentation
  • Evaluation of volumetry vs. RECIST
  • Estimating the clinical impact of volumetry
  • Its likely to reduce errors by a factor of 5
  • 11:40 CLINICAL SITE QUALIFICATION FOR DCE-MRI IMAGING

    Donald Cooper RT (R) (MR)

    Donald Cooper RT (R) (MR), Director, Project Management, Biomedical Systems

  • Site selection criteria (equipment, experience)
  • Standardized imaging protocol across multiple imaging vendors
  • Equipment evaluation and test data a must
  • Communication key for good image quality and protocol adherence
  • DICOM transfer/hard copy transfer of data to the imaging core lab
  • 12:20 Networking Lunch

    14:00 NANOTECHNOLOGY FOR CANCER IMAGING

    Professor Tobias Schaeffter

    Professor Tobias Schaeffter, Philip Harris Chair in Imaging Sciences, Division of Imaging Sciences , King's College London

  • Quantitative MRI
  • Cancer diagnosis with magnetic naoparticles
  • Image guided delivery of nanoparticles for cancer therapy
  • Tracking of labelled cells
  • Nanoparticles for molecular imaging agents
  • 14:40 THE PHARMACEUTICAL SCOPE OF LOCKED NUCLEIC ACID

    Bo Hansen

    Bo Hansen, Associate Director, Molecular Biology, Santaris Pharma

  • Outline of the chemical and biophysical properties of LNA
  • Regulation of mRNA and microRNA target expression by LNA
  • Examples from oncology targets
  • Uptake, distribution and PK of LNA oligonucleotides
  • Status on development programs
  • 15:20 Chairman’s Closing Remarks, followed by Afternoon Tea

    +

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.